Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

New Analyses of Data From RE-LY Trial, Involving Oral Anticoagulant Pradaxa, to be Presented at American Heart Association’s Scientific Sessions

November 11, 2010 By Bio-Medicine.Org

RIDGEFIELD, Conn., Nov. 11, 2010 /PRNewswire/ — Results
of two pre-specified sub-study analyses of the 18,113 patient
RE-LY® trial,(1) involving the newly approved oral
anticoagulant Pradaxa® (dabigatran etexilate mesylate)
capsules,(2) will be presented at the American Heart Association’s
Annual Scientific Sessions on Monday, November 15, 2010.  The
analyses assessed the prognostic value of two separate biomarkers
(D-dimer and NT-proBNP) for predicting cardiovascular events in
patients with non-valvular atrial fibrillation (AFib).(3,4)

RE-LY® was a global, Phase III, randomized trial, which
investigated whether PRADAXA was as effective as well-controlled
warfarin (open label) for stroke prevention in patients with
non-valvular atrial fibrillation.(1) The study provided the basis
for the U.S. Food and Drug Administration’s (FDA) recent approval
of PRADAXA to reduce the risk of stroke and systemic embolism in
patients with non-valvular atrial fibrillation.(2)

Well-controlled warfarin, defined as INR 2.0 – 3.0, has
been shown to reduce the risk of stroke in patients with
non-valvular atrial fibrillation.(5)  Results of the
RE-LY® trial demonstrated PRADAXA 150mg taken twice daily
significantly reduced stroke and systemic embolism by 35 percent
beyond the reduction achieved with warfarin.(2) PRADAXA 150mg taken
twice daily also significantly reduced both ischemic and
hemorrhagic strokes compared to warfarin.(2)

PRADAXA is the only approved oral anticoagulant that has been
shown to significantly reduce the risk of stroke compared to
warfarin(2) and is the first oral anticoagulant to be approved in
the U.S. in more than 50 years.  PRADAXA is now available in
more than 35,000 pharmacies nationwide.  

About RE-LY®

RE-LY® was a global, Phase III, randomized trial(1) of
18,113 patients(1) enrolled in 951 centers in 44 countries,(6)
investigating whether PRADAXA (two b

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 27, 2022
Quick message - No DTW podcast, but plenty else to listen to over this weekend and next week.
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech